148 related articles for article (PubMed ID: 24324108)
1. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
2. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.
Da Fonseca CO; Silva JT; Lins IR; Simão M; Arnobio A; Futuro D; Quirico-Santos T
Invest New Drugs; 2009 Dec; 27(6):557-64. PubMed ID: 19139816
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca CO; Schwartsmann G; Fischer J; Nagel J; Futuro D; Quirico-Santos T; Gattass CR
Surg Neurol; 2008 Sep; 70(3):259-66; discussion 266-7. PubMed ID: 18295834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
Da Fonseca CO; Masini M; Futuro D; Caetano R; Gattass CR; Quirico-Santos T
Surg Neurol; 2006 Dec; 66(6):611-5. PubMed ID: 17145324
[TBL] [Abstract][Full Text] [Related]
7. Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
Faria GM; Soares IDP; D'Alincourt Salazar M; Amorim MR; Pessoa BL; da Fonseca CO; Quirico-Santos T
BMC Cancer; 2020 Apr; 20(1):294. PubMed ID: 32264844
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol.
da Fonseca CO; Landeiro JA; Clark SS; Quirico-Santos T; da Costa Carvalho Mda G; Gattass CR
Surg Neurol; 2006; 65 Suppl 1():S1:2-1:8; discussion S1:8-1:9. PubMed ID: 16427438
[TBL] [Abstract][Full Text] [Related]
9. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Robins HI; Chang SM; Prados MD; Yung WK; Hess K; Schiff D; Greenberg H; Fink K; Nicolas K; Kuhn JG; Cloughesy T; Junck L; Mehta M
Neuro Oncol; 2002 Apr; 4(2):109-14. PubMed ID: 11916502
[TBL] [Abstract][Full Text] [Related]
12. Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.
da Silveira Fd; Lopes Bde A; da Fonseca CO; Quirico-Santos T; de Palmer Paixão IC; de Amorim LM
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1347-54. PubMed ID: 22481252
[TBL] [Abstract][Full Text] [Related]
13. Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells.
Fernandes J; da Fonseca CO; Teixeira A; Gattass CR
Oncol Rep; 2005 May; 13(5):943-7. PubMed ID: 15809762
[TBL] [Abstract][Full Text] [Related]
14. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy.
Faria G; Silva E; Da Fonseca C; Quirico-Santos T
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848970
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.
Chen TC; da Fonseca CO; Schönthal AH
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563210
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]